Efficacy and safety of liraglutide 3.0 mg for weight management are similar across races: Subgroup analysis across the SCALE and phase II randomized trials

Diabetes, Obesity and Metabolism

Volumn 18, Issue 4, 2016, Pages 430-435

  Ard, J ^a   Cannon, A ^b   Lewis, C E ^c   Lofton, H ^d   Vang Skjoth T ^e   Stevenin, B ^f   Pi Sunyer, X ^g  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b Endocrine Metabolic Associates   (United States)

^c University of Alabama at Birmingham   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NOVO NORDISK A S   (Denmark)

^f NOVO NORDISK INC   (United States)

^g Columbia University ^*  (United States)

Author keywords

Antiobesity drug; Clinical trial; Glucagon like peptide 1 analogue; Liraglutide; Obesity therapy; Randomized trial

Indexed keywords

LIRAGLUTIDE; PLACEBO; ANTIDIABETIC AGENT; ANTIOBESITY AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; AFRICAN AMERICAN; ARTICLE; ASIAN; BLACK PERSON; BODY MASS; BODY WEIGHT MANAGEMENT; CARDIOVASCULAR RISK; CAUCASIAN; COMORBIDITY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ETHNIC DIFFERENCE; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; MALE; METABOLIC REGULATION; OBESITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; WEIGHT REDUCTION; ADVERSE EFFECTS; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; ETHNOLOGY; EXERCISE; HYPERGLYCEMIA; LOW CALORY DIET; MULTIMODALITY CANCER THERAPY; OVERWEIGHT; PHASE 2 CLINICAL TRIAL; PREDIABETIC STATE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ANTI-OBESITY AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BODY MASS INDEX; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 2; DIET, REDUCING; DOUBLE-BLIND METHOD; EUROPEAN CONTINENTAL ANCESTRY GROUP; EXERCISE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; MALE; OBESITY; OVERWEIGHT; PREDIABETIC STATE; QUALITY OF LIFE; WEIGHT LOSS;

EID: 84959919583     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12632     Document Type: Article

References (15)

1. OECD. Obesity and the economics of prevention: fit not fat. Key facts - England, update 2014. Available from URL: http: www.oecd.org/unitedkingdom/Obesity-Update-2014-ENGLAND.pdf. Accessed 16 December 2015.
2. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA 2014; 311: 806-814.
3. Wingo BC, Carson TL, Ard J. Differences in weight loss and health outcomes among African Americans and whites in multicentre trials. Obes Rev 2014; 15: 46-61.
4. Jensen MD, Ryan DH, Donato KA et al. Executive summary: guidelines (2013) for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Obesity Society Published by the Obesity Society. Obesity 2014; 22(Suppl. 2): S5-39.
5. Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean ME. Safety, tolerability and sustained weight loss over 2 years with once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) 2012; 36: 843-854.
6. Pi-Sunyer X, Astrup A, Fujioka K et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015; 373: 11-22.
7. Davies MJ, Bergenstal R, Bode B et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA 2015; 314: 687-699.
8. Wadden TA, Hollander P, Klein S et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study. Int J Obes 2013; 37: 1443-1451.
9. Blackman A, Foster G, Zammit G et al. Liraglutide 3.0 mg reduces severity of obstructive sleep apnoea and body weight in obese individuals with moderate or severe disease: SCALE sleep apnoea trial. Diabetologia 2014; 57(Suppl. 1): S85.
10. Aronne L, Shanahan W, Fain R et al. Safety and efficacy of lorcaserin: a combined analysis of the BLOOM and BLOSSOM trials. Postgrad Med 2014; 126: 7-18.
11. The Look AHEAD. Research Group Eight-year weight losses with an intensive lifestyle intervention: the Look AHEAD study. Obesity 2014; 22: 5-13.
12. Pencek R, Blickensderfer A, Li Y, Brunell SC, Anderson PW. Exenatide twice daily: analysis of effectivenes and safety data stratified by age, sex, race, duration of diabetes, and body mass index. Postgrad Med 2012; 124: 21-32.
13. Peterson GE, Pollom RD. Liraglutide in clinical practice: dosing, safety and efficacy. Int J Clin Pract Suppl 2010; 167: 35-43.
14. Rejeski WJ, Ip EH, Bertoni AG et al. Lifestyle change and mobility in obese adults with type 2 diabetes. N Engl J Med 2012; 366: 1209-1217.
15. Warkentin LM, Das D, Majumdar SR, Johnson JA, Padwal RS. The effect of weight loss on health-related quality of life: systematic review and meta-analysis of randomized trials. Obes Rev 2014; 15: 169-182.